In today’s briefing:
- Paramount Bed (7817 JP): Poised to Grow on the Back of Recovery from the COVID-19
- Shenzhen Chipscreen Biosciences (688321.CH) – Risks Outweigh Opportunities
Paramount Bed (7817 JP): Poised to Grow on the Back of Recovery from the COVID-19
- Paramount Bed Holdings Co Lt (7817 JP) reported record-high sales and profit during six-month ended on September 30, 2021, driven by strong domestic demand due to recovery from the pandemic.
- Each of businesses are receiving steady inquiries from market and is expected to perform strongly. Management raised full-year guidance after a strong Q1 results.
- New products are driving margin for the company. Nemuri SCAN continues to perform well as remote monitoring using sensor technology is receiving more attention amid the COVID-19 pandemic.
Shenzhen Chipscreen Biosciences (688321.CH) – Risks Outweigh Opportunities
- The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain.
- The continuous large investment in R&D, high selling expenses, and declining R&D expending capitalization would further drag down profitability.
- So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.
Before it’s here, it’s on Smartkarma
